News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advaxis, Inc. Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer



5/8/2012 10:18:44 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two patients have been enrolled into REALISTIC, a Phase 1/2 study being sponsored by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES